Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3

Graphical abstract

Highlights
- Immune escape of 50 human mAbs by Omicron sub-variants was assessed
- Omicron sub-variants BA.1, BA.1.1, BA.2, and BA.3 have similar immune evasion spectra
- BA.2 is more sensitive to RDB-5 mAbs due to the lack of G446S mutation

Authors
Min Huang, Lili Wu, Anqi Zheng, ..., Jianxun Qi, Qihui Wang, George Fu Gao

Correspondence
jxqi@im.ac.cn (J.Q.), wangqihui@im.ac.cn (Q.W.), gaof@im.ac.cn (G.F.G.)

In brief
The evolution of SARS-CoV-2 variants of concern brings new challenges toward host immunity and protection. Huang et al. tested the neutralization potency of 50 human mAbs against Omicron sub-variants BA.1, BA.1.1, BA.2, and BA.3. Structural analysis of three mAbs provides further insight into the immune evasion capacity of Omicron sub-variants.
Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3

Min Huang, Lili Wu, Anqi Zheng, Yufeng Xie, Qingwen He, Xiaoyu Rong, Pu Han, Pei Du, Pengcheng Han, Zengyuan Zhang, Runchu Zhao, Yunfei Jia, Linjie Li, Bin Bai, Ziliang Hu, Shixiong Hu, Sheng Niu, Yu Hu, Honghui Liu, Bo Liu, Kaige Cui, Weiwei Li, Xin Zhao, Kefang Liu, Jianxun Qi, Qihui Wang, and George Fu Gao

SUMMARY

SARS-CoV-2 Omicron variant has presented significant challenges to current antibodies and vaccines. Herein, we systematically compared the efficacy of 50 human monoclonal antibodies (mAbs), covering the seven identified epitope classes of the SARS-CoV-2 RBD, against Omicron sub-variants BA.1, BA.1.1, BA.2, and BA.3. Binding and pseudovirus-based neutralizing assays revealed that 37 of the 50 mAbs lost neutralizing activities, whereas the others displayed variably decreased activities against the four Omicron sub-variants. BA.2 was found to be more sensitive to RBD-5 antibodies than the other sub-variants. Furthermore, a quaternary complex structure of BA.1 RBD with three mAbs showing different neutralizing potencies against Omicron provided a basis for understanding the immune evasion of Omicron sub-variants and revealed the lack of G446S mutation accounting for the sensitivity of BA.2 to RBD-5 mAbs. Our results may guide the application of the available mAbs and facilitate the development of universal therapeutic antibodies and vaccines against COVID-19.

INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been ravaging the world since the end of 2019 (Jiang et al., 2020; Tan et al., 2020; Zhu et al., 2020). In over 2 years, this novel coronavirus has infected over 500 million people worldwide, causing over six million deaths and great economic loss (https://covid19.who.int). In addition, SARS-CoV-2 continues to mutate and generate new variants, including Alpha, Beta, Gamma, and Delta variants of concern (VOC). A new VOC, named Omicron, with an alarmingly fast transmission rate, has recently emerged (Karim and Karim, 2021; WHO, 2021a). Confirmed cases of Omicron doubled in 1.5–3 days in areas (e.g., South Africa and the neighboring countries) with community transmission, which is significantly faster than that of Delta (Grabowski et al., 2022; WHO, 2021b). So far, Omicron has spread to all six geographic regions, surpassed Delta as the dominant VOC in many countries (https://nextstrain.org/ncov/gisaid/global), and developed several sub-lineages (e.g., BA.1, BA.1.1, BA.2, BA.3, BA.4, BA.5, and BA.2.12.1). BA.1 represented the majority of Omicron VOC until the end of 2021, at which point BA.1.1 was increasing. As of March 2022, BA.2 has surpassed BA.1 as the dominant sub-variant (WHO, 2022).

The most noticeable feature of Omicron is the surprisingly high number of mutations that are disproportionately concentrated in the spike (S) protein. BA.1 has 50-amino acid mutations in its genome, 33 of which are in the S protein. Fifteen of these are...
located in the receptor-binding domain (RBD) of the S protein, which is the main component included in COVID-19 vaccines, as well as the main target for neutralizing monoclonal antibodies (mAbs) (Han et al., 2022). BA.1.1 contains one more mutation (R346K) on the basis of BA.1. Additional mutations in the S protein and RBD also separate BA.2 and BA.3 from BA.1 (Figure 1). In the RBD, BA.1, BA.1.1, BA.2, and BA.3 share 12 mutations (G339D, S373P, S375P, K417N, N440K, S477N, T483K, E484A, Q493R, Q498R, N501Y, and Y505H), with one residue (S371) mutated to L371 in BA.1 and F371 in both BA.2 and BA.3. Additionally, compared with BA.1, BA.2 contains three more mutations (T376A, D405N, and R408S) but lacks G446S. BA.3 includes D405N but not G446S. Many of these mutations were rarely seen in previous VOCs (e.g., G339D, S375F, and Y505H), signifying the mystery of the origins of Omicron (Du et al., 2022).

Importantly, however, some mutation sites in the RBD—such as K417, E484, and N501—are well known for causing immune escapes (Harvey et al., 2021; Li et al., 2021, 2022; Zhou et al., 2021), although previously rare mutations represent new sites that may lead to further immune escapes. Such mutations identified in the RBD raise questions regarding the efficacy of the vaccines and antibodies currently in use against Omicron. Answers to these questions may determine the outcome of global efforts to develop herd immunity against SARS-CoV-2. Multiple reports estimate that the efficacy of some mRNA and adenoviral vector vaccines (mRNA-1273/BNT162b2 and ChAdOx1, respectively) against Omicron sub-variant BA.1, BA.1.1, BA.2, and BA.3, as well as their ability to neutralize Omicron pseudoviruses. Moreover, to reveal molecular mechanisms of immune escape of Omicron, we solved the structure of a quaternary complex of Omicron BA.1 RBD with three antibodies from different groups (RBD-1, RBD-5, and RBD-7) with different neutralizing potencies. Our data demonstrate the effectiveness of a wide range of currently used SARS-CoV-2 antibodies and may facilitate the development of universal therapeutic antibodies and vaccines to fight the ongoing COVID-19 pandemic.

RESULTS

The majority of antibodies lost binding affinity toward Omicron

To evaluate the efficacy of current human mAbs against dominant Omicron sub-variants, we first determined the binding affinities between a panel of 50 RBD-targeting neutralizing mAbs and Omicron sub-variant RBDs (BA.1, BA.1.1, BA.2, and BA.3) via surface plasmon resonance (SPR) assays with the Prototype RBD and Delta RBD for comparison (Figure 1; Table S1). According to their epitopes, these 50 mAbs (Table S1), including several in-clinical use or under development, were divided into seven groups (from RBD-1 to RBD-7) as previously defined (Hastie et al., 2021). RBD-1 (16), RBD-2 (11), and RBD-3 (1) recognize the RBD, whereas antibodies in groups RBD-6 and RBD-7 bind to the inner face of the RBD (Figure 1).

In this study, we selected 50 human mAbs that cover all seven groups of epitopes in the RBD to investigate their effectiveness against Omicron sub-variants. We assessed the binding of these antibodies to the RBDs of Omicron sub-variant BA.1, BA.1.1, BA.2, and BA.3, as well as their ability to neutralize Omicron pseudoviruses. Moreover, to reveal molecular mechanisms of immune escape of Omicron, we solved the structure of a quaternary complex of Omicron BA.1 RBD with three antibodies from different groups (RBD-1, RBD-5, and RBD-7) with different neutralizing potencies. Our data demonstrate the effectiveness of a wide range of currently used SARS-CoV-2 antibodies and may facilitate the development of universal therapeutic antibodies and vaccines to fight the ongoing COVID-19 pandemic.

Figure 1. Amino acid mutation mapping of RBDs from SARS-CoV-2 Prototype and VOCs

Three major epitopes on SARS-CoV-2 RBD targeted by seven classes of mAbs (RBD-1–RBD-7) and residue mutation mapping of RBDs from SARS-CoV-2 VOCs. See also Table S1.
| Binding affinity (K<sub>D</sub>: nM) | Pseudovirus neutralization (IC<sub>50</sub>: μg/ml) |
|----------------------------------|-----------------------------------------------|
| **Class** | **Abs** | BA.1 | BA.1.1 | BA.2 | BA.3 | Delta | PT | **BA.1** | **BA.1.1** | **BA.2** | **BA.2+ G446S** | **BA.3** | Delta | PT |
| RBD-1 | | | | | | | | | | | | | | |
| CB6 | - | - | 871.4 | 13.3 | 27.2 | | | >100 | >100 | >100 | >100 | >100 | 0.008 | 0.02 |
| B38 | - | - | 3500 | 535.6 | 94.6 | 226.1 | | >100 | >100 | >100 | >100 | >100 | 0.059 | 1.76 |
| BD-236 | - | - | 2094 | 2.5 | 7.8 | | | >100 | >100 | >100 | >100 | >100 | 0.038 | 0.065 |
| BD-604 | 6.1 | 14.7 | 11.1 | 2.0 | 0.002 | 0.05 | | 0.17 | 0.049 | 0.1 | 0.066 | 0.013 | 0.23 | 0.027 |
| BD-629 | 19.2 | 26.6 | 97.1 | 58.0 | 0.1 | 0.8 | | 0.78 | 1.356 | 0.98 | 2.5 | 1.08 | 0.014 | 0.03 |
| C102 | 235.8 | 1061 | 456.4 | 432.2 | 19.6 | 49.0 | | >100 | >100 | >100 | >100 | >100 | 0.02 | 0.067 |
| C105 | - | - | 2460 | 9.3 | 17.4 | | | >100 | >100 | >100 | >100 | >100 | 0.034 | 0.15 |
| C1A-B3 | - | - | - | - | 20.1 | 41.9 | | >100 | >100 | >100 | >100 | >100 | 0.01 | 0.03 |
| C1A-C2 | - | - | - | - | 7.4 | 17.2 | | >100 | >100 | >100 | >100 | >100 | 0.01 | 0.021 |
| C1A-F10 | - | - | - | - | 5.7 | 16.8 | | >100 | >100 | >100 | >100 | >100 | 0.018 | 0.017 |
| C12.1 | 203.9 | 451.3 | 584.9 | 880.2 | 10.4 | 23.3 | | >100 | >100 | >100 | >100 | >100 | 0.012 | 0.007 |
| C12.3 | 181.4 | 412.0 | 180.3 | 363.8 | 6.6 | 13.5 | 16.54 | 5.42 | 20.54 | 18.56 | 3.03 | 0.003 | 0.003 |
| COVA2-04 | - | - | - | - | 26.8 | 55.5 | | >100 | >100 | >100 | >100 | >100 | 0.23 | 1.23 |
| CV30 | 160.1 | 778 | 668.1 | 1038 | 4.2 | 8.4 | | >100 | >100 | >100 | >100 | >100 | 0.013 | 0.046 |
| P2C-1F11 | 41.8 | 70.8 | 61.1 | 39.8 | 3.1 | 6.3 | 3.81 | 2.62 | 0.53 | 1.04 | 2.57 | 0.012 | 0.039 |
| C104 | - | - | - | - | 920.9 | 734.7 | | >100 | >100 | >100 | >100 | >100 | 0.45 | 0.86 |
| C1A-F10 | - | - | - | - | 20.0 | 41.9 | | >100 | >100 | >100 | >100 | >100 | 0.01 | 0.03 |
| C1A-C2 | - | - | - | - | 7.4 | 17.2 | | >100 | >100 | >100 | >100 | >100 | 0.01 | 0.021 |
| C1A-F10 | - | - | - | - | 5.7 | 16.8 | | >100 | >100 | >100 | >100 | >100 | 0.018 | 0.017 |
| C12.1 | 203.9 | 451.3 | 584.9 | 880.2 | 10.4 | 23.3 | | >100 | >100 | >100 | >100 | >100 | 0.012 | 0.007 |
| CC12.3 | 181.4 | 412.0 | 180.3 | 363.8 | 6.6 | 13.5 | 16.54 | 5.42 | 20.54 | 18.56 | 3.03 | 0.003 | 0.003 |
| COVA2-04 | - | - | - | - | 26.8 | 55.5 | | >100 | >100 | >100 | >100 | >100 | 0.23 | 1.23 |
| CV30 | 160.1 | 778 | 668.1 | 1038 | 4.2 | 8.4 | | >100 | >100 | >100 | >100 | >100 | 0.013 | 0.046 |
| P2C-1F11 | 41.8 | 70.8 | 61.1 | 39.8 | 3.1 | 6.3 | 3.81 | 2.62 | 0.53 | 1.04 | 2.57 | 0.012 | 0.039 |

Figure 2. Binding and neutralizing abilities of current antibodies to Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-variants

50 mAbs were divided into seven groups (RBD-1–RBD-7) shown in different colors. The indicated antibodies in the supernatant were captured by a Protein A chip. Then, serially diluted Omicron RBD, Delta RBD, and Prototype RBD were flowed over the chip surface to assess binding to the indicated antibodies, respectively.
and 30-fold decreases, respectively, in binding to Delta RBD (Figures 2, S1, and S2).

Of the 16 mAbs in RBD-1, five (C1A-B3, CA1-C2, C1A-F10, COV2A-04, and S2H14) completely lost the ability to bind all four Omicron sub-variant RBDs (Figure 2). Four (CB6 [LY-CoV16], B38, BD-236, and C105) retained the ability to bind BA.3 RBD, but their affinities were relatively low, with equilibrium dissociation constants (K_D) > 500 nM. B38 also retained weak binding ability to BA.2 RBD, but others showed no binding to BA.2 RBD. Four (C102, CC12.1, CC12.3, and CV30) bound all four Omicron RBDs with micromolar or submicromolar affinities. Three [BD-604, BD-629, and P2C-1F11] showed relatively low binding affinity to Omicron sub-variants with affinities ranging from 11.9 to 114.0 nM.

The single mAb in RBD-3, ADI-56046, showed relatively low binding to BA.1, BA.1.1, and BA.3 RBDs, with K_D values of 2.3, 1.5, and 18.0 µM, respectively, and completely lost the ability to bind to BA.2 RBD (Figure 2).

The seven mAbs in RBD-4, five (C002, C104, P17, P2B-2F6, and S2H13) completely lost the ability to bind to four Omicron sub-variant RBDs with the exception of P17 and P2B-2F6, which bound, respectively, to BA.3 RBD and BA.2 RBD with K_D values of 3.5 and 5.1 µM, respectively. BD-386-2 and CV07-270 showed low binding to the four Omicron sub-variant RBDs just as P17 did to BA.3 RBD. In short, the mAbs in RBD-4 showed complete failure or relatively low abilities to bind to Omicron sub-variant RBDs.

Of the seven mAbs in RBD-5, two (C135 and 47D11) failed to bind to four Omicron RBDs. C110 and 2H04 showed micromolar or submicromolar binding to Omicron RBDs, and 2H04 lost binding to BA.1.1 RBD. REGN10987 also displayed micromolar binding to BA.1, BA.1.1, and BA.3 RBDs but showed relatively high binding to BA.2 RBD, with a K_D value of 56.7 nM as it does to Prototype RBD. C119 lost binding to BA.1, BA.1.1, and BA.3 RBDs but showed micromolar binding to BA.2 RBD. Notably, S309—the parent antibody of sotrovimab—retained nanomolar binding affinities to four Omicron sub-variant RBDs but displayed 2.3-fold 14-fold decreases.

All three mAbs in RBD-6 (COVA1-16, C022, and 2-36) showed binding affinities to four Omicron sub-variant RBDs similar as those to Prototype RBD and Delta RBD. Of the five mAbs in RBD-7, H014 and S2A4 showed remarkably decreased binding, CR3022 and S304 showed similar binding, and EY6A showed moderately increased binding to Omicron RBDs compared with that to Prototype RBD and Delta RBD. Overall, most mAbs in RBD-6 and RBD-7 retained similar binding to Omicron sub-variant RBDs as to Prototype RBD, whereas mAbs in the other five groups displayed variable decreased affinities in binding to Omicron sub-variant RBDs.

The majority of antibodies lost neutralizing potency against Omicron

Based on most mAbs showing a complete loss or dramatic reduction in binding to Omicron sub-variant RBDs, we further evaluated the neutralizing activities of these 50 mAbs against four Omicron sub-variants by pseudovirus assays. As expected, in RBD-1, 12 of the 16 mAbs (CB6, B38, BD-236, C102, C105, C1A-B3, CA1-C2, C1A-F10, CC12.1, COV2A-04, CV30, and S2H14) failed to neutralize the four Omicron sub-variants, which is consistent with their failed or poor binding to Omicron sub-variant RBDs (Figures 2 and S3). BD-604, BD-629, and P2C-1F11 showed partially decreased (10- to 100-fold) neutralizing abilities against Omicron sub-variants compared with Prototype or Delta strain, with half-maximal inhibitory concentrations (IC_{50}) values of <1 µg/mL or ~1 µg/mL (Figures 2 and S2). BD-604 was the most potent among the 16 RBD-1 neutralizing mAbs. CC12.3 showed a relatively weak neutralization against Omicron sub-variants, with IC_{50} values ranging from 5 to 25 µg/mL. CC12.1 completely lost inhibition to Omicron sub-variants, although CC12.1 and CC12.3 share the IGHV3-53 heavy chain (Yuan et al., 2020a). In RBD-2, 10 of 11 mAbs (REGN10933, LY-CoV555, Ab23, COVA2-39, C121, CC12.1, P2C-1A3, H4, S2M11, and 2-4) lost the ability to neutralize the four Omicron sub-variants due to its poor or failed bindings to Omicron sub-variant RBDs.

All seven mAbs (BD-368-2, C002, C104, COV07-270, P17, P2B-2F6, and S2H13) in RBD-4 also failed to neutralize the four Omicron sub-variants due to their poor or failed bindings to Omicron RBDs. In RBD-5, three of the seven mAbs (C119, C135, and 47D11) completely lost the ability to neutralize the four Omicron sub-variants due to their poor or failed binding. However, although REGN10987, C110, and 2H04 failed to neutralize the BA.1, BA.1.1, and BA.3 sub-variants, all of them could neutralize the BA.2 sub-variant with different potencies; this was particularly true of REGN10987, the IC_{50} of which was 0.45 µg/mL. S309 showed moderately reduced (<10-fold) neutralization against Omicron sub-variants compared with that against the Delta and Prototype strains (Figure S2), which is consistent with the results of several recent studies (Liu et al., 2022; Planas et al., 2022; VanBlargan et al., 2022).

In RBD-6, all three mAbs (COVA1-16, C022, and 2-36) exhibited relatively weak neutralization against the four Omicron sub-variants; however, they showed similar binding to Omicron RBDs compared with the Prototype RBD. As previously reported (Yuan et al., 2020b), CR3022 in RBD-7 cannot neutralize SARS-CoV-2 and its variants including Delta and Omicron. H014, S2A4,
| Prototype | S | S' | S'1 | S'2 | S'3 | Bc2 | TT | Bc3 |
|-----------|---|----|-----|-----|-----|-----|----|-----|
| BA. 1     | 420 | 410 | 240 | 240 | 360 | 360 | 390 | 390 |
| BA. 1.1   | 420 | 410 | 240 | 240 | 360 | 360 | 390 | 390 |
| BA. 2     | 420 | 410 | 240 | 240 | 360 | 360 | 390 | 390 |
| BA. 3     | 420 | 410 | 240 | 240 | 360 | 360 | 390 | 390 |

BD-604 on both RBDs
BD-604 on Omicron RBD
BD-604 on Prototype RBD
S309 on both RBDs
S309 on Omicron RBD
S309 on Prototype RBD
S304 on both RBDs
S304 on Prototype RBD

(legend on next page)
and S304 lost the ability to neutralize the Omicron sub-variants; however, EY6A showed a moderately reduced or similar ability against the Omicron sub-variants compared with that against Prototype and Delta strains. Overall, among the 50 mAbs, 37 completely failed to neutralize all four Omicron sub-variants, seven (CC12.3, P2C-1F11, C110, 2H04, COVA1-16, C022, and 2-36) showed relatively weak neutralizing abilities against 1–2 Omicron sub-variants (IC50 >1 μg/mL), and others (BD-604, BD-629, S2E12, REGN10987, S309, and EY6A) retained relatively high abilities to neutralize 1–2 Omicron sub-variants (IC50 <1 μg/mL) at our tested concentrations. Only BD-604 and S309 retained potent neutralizing activity against all four Omicron sub-variants, indicating remarkable immune escape of these Omicron sub-variants.

Compared with the Omicron sub-variants, these 50 mAbs showed equal or increased neutralizing activities against the Delta variant; the exceptions were BD368-2, CV07-270, C002, and C104 in RBD-4, which showed failed or remarkably decreased abilities to neutralize Delta (Figures 2 and S2). As previously reported (Planas et al., 2021b), we also found that RBD-2 mAb LY-CoV555 showed a decreased neutralizing ability against Delta.

The overall structure of Omicron BA.1 RBD in complex with three mAbs targeting the RBM, outer face, and inner face of RBD

After screening of the 50 mAbs, we noticed that there were three mAbs, BD-604 (RBD-1, RBM), S309 (RBD-5, outer face), and S304 (RBD-7, inner face), which showed sub-nanomolar to nanomolar binding to the four Omicron RBDs but exhibited different neutralizing potencies against the four Omicron sub-variants. BD-604 and S309 partially and moderately reduced the neutralizing activity, respectively, whereas S304 completely abolished its potency. To understand the molecular basis of these variations, together with the mechanisms of Omicron escaping of seven groups of antibodies, we determined the quaternary complex structure of Omicron BA.1 RBD with the three mAbs at a resolution of 2.79 Å using cryo-electron microscopy (cryo-EM) (Table S2; Figure S4).

The overall architecture resembles the previously reported structure (PDB:7JX3) of the Prototype RBD in complex with S2H14 (RBD-1), S309, and S304 (Figure 3A) (Piccoli et al., 2020). Fifteen mutations in Omicron BA.1 RBD were displayed, of which ten (K417N, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, and Y505H) were distributed in the RBM and five (G339D, S371L, S373P, S375F, and N440K) were in the outer face and inner face of the RBD (Figure 3B). Omicron S is preferentially in a state with one up-RBD or three down-RBDs, showing a more stable feature than Prototype S and Delta S (Cui et al., 2022; Hong et al., 2022). Thus, we first superimposed the quaternary complex structure onto the Omicron BA.1 S (PDB:7QO7) in one-RBD-up conformation. This revealed that BD-604 and S309 did not clash with the adjacent RBD or NTD, whereas S304 displayed a clear steric hindrance with the adjacent RBD (Figures 3C–3E).

The molecular basis of the immune evasion of mAbs targeting the RBM of RBD by Omicron

BD-604, as well as other antibodies in RBD-1, RBD-2, and RBD-3, recognize the RBM and generally bind up-RBD and neutralize SARS-CoV-2 infection by competition with the ACE2 receptor (Cao et al., 2020; Shi et al., 2020; Wu et al., 2020). Although BD-604 showed no clash with the adjacent protomer when binding to the S trimer, seven mutations (K417N, S477N, Q493R, G496S, Q498R, N501Y, and Y505H) in the Omicron RBD were included in its binding epitope (Figures 3F and 4D; Table S3). Based on the reported complex structure of BD-604 binding to Prototype RBD (PDB:7CH4), we found that the binding face displayed electrostatic complementary interactions, particularly the positively charged bulge on Prototype RBD formed by K417, which inserted into the negatively charged groove formed by the heavy chain (H) and light chain (L) of BD-604 (circle a, Figures 4A and 4B). However, the K417N mutation reduced the positively charged features of the Omicron RBD (Figure 4C). In addition, although T478 is not included in the epitope of BD-604, K478, with a positive charge, strengthened the electrostatic repulsion between RBD and the H chain of the antibody (circle b). These factors led to BD-604 binding to Omicron RBD with approximately a 3 Å shift compared with that bound to Prototype RBD (Figure 4D), and this may also be enhanced by Q493R and Q498R mutations due to the longer side chain of arginine. Furthermore, we found that five hydrogen bonds (H-bonds) between the H chain of BD-604 and RBD were broken, which were contributed by G26 (HCDR1) with N487, S33 (LCDR2) with Y421, S53 with R457, and R97 (HCDR3) with Y489 (Figures 4E and 4F; Table S6), and three H-bonds between the L chain and RBD were broken, which were formed by Q27 (LCDR1) with G502, G28 (LCDR1) with G502, and N92 (LCDR3) with R403 (Figures 4G and 4H; Table S6). The Q493R and Q498R mutations resulted in the loss of four H-bonds formed by Y102 (HCDR3) with Q493, S30 (LCDR1) with Q498, and S67 (LCDR2) with Q498 (Figures 4E–4H). BD-604 completely and partially lost the van der Waals interaction with S496 and N477 as compared with that with G496 and S477 (Table S3). However, N501Y and Y505H mutations enhanced the interaction with BD-604 (Figures 4G and 4H; Table S3). Moreover, the L chain of BD-604 formed two new salt bridges with Omicron RBD by the interaction of D32 with R493 and D94 with R408 (Figures 4G and 4H; Table S6),
Figure 4. Structural details of immune evasion of BD-604 and related antibodies by Omicron sub-variants

(A) Electrostatic surface view of BD-604.
(B) Electrostatic surface view of Prototype RBD.
Although BD-604 maintained considerable interaction with Omicron, its binding was lower than that to Prototype RBD because of the seven mutations included in its epitope (Figure 3F). These results could explain why BD-604 exhibited reduced neutralization ability against Omicron (Figure 2). We confirmed that the decrease in the neutralization of most antibodies recognized RBM (RBD-1, RBD-2, and RBD-3) was caused by residue mutations, including used LY-CoV16 (CB6), LY-CoV-555, and REGN10933. For representative CB6, the K417N mutation broke the salt bridge interaction with D104 in the H chain, and the Q493R mutation displayed steric hindrance with Y102 in the H chain because of the longer side chain of R (Figure 4I). These results led to CB6 losing the binding and neutralizing abilities to the four Omicron sub-variants because all of them bear K417N and Q493R mutations. In addition, for CC12.1 and CC12.3, the H chains—which use the same germline gene (IGHV3-53)—four mutations (K417N, S477N, E484A, and Q493R) carried by all four Omicron sub-variants led to the loss of many interactions with CC12.1, including those containing salt bridges, H-bonds, and van der Waals interactions, as well as the addition of a steric clash that resulted in the failed neutralization of CC12.1 against the Omicron sub-variants (Figure 4J). However, just two mutations K417N and Q493R affected its interaction with CC12.3 (Figure 4K). Thus, these results could explain why CC12.3 shows slightly better binding and neutralization to Omicron than CC12.1 (Figure 2).

The molecular basis of the immune evasion of mAbs targeting the outer face of RBD by Omicron

S309, as well as other mAbs in RBD-5 and RBD-4, recognize the outer face of the RBD, bind both up-RBD and down-RBD within the S trimer, and potently neutralize SARS-CoV-2 by cross-linking spike proteins (Pinto et al., 2020). Compared with the previous report of the structure of S309 in complex with Prototype RBD (PDB:7JX3), we found that S309 bound to Omicron RBD was similar to that bound to Prototype RBD, with a ~1.8 Å shift (Figure 5A; Tables S6); two mutations in Omicron, G339D and N440K, contributed to the interaction with S309 (Figures 3F and 5A). The G339D mutation resulted in the loss of two H-bonds formed by the interaction of Y100 (HCDR3) and G339 (Figure 5B). Moreover, the glycosylation of N343 was heavier with two NAGs and one fucose (FUC) and formed more interactions with S309 than that in Prototype RBD (Figure 5C, left panel). These results could explain why S309 showed only moderately reduced binding and neutralization ability against the three Omicron sub-variants (Figure 2). However, other antibodies in RBD-5 and RBD-4 showed reduced neutralization against Omicron (Figure 2). For example, REGN10987, the epitope of which is closer to RBM than S309, and the binding is mainly affected by G446S and N440K mutations (Figure 5G). The G446S mutation breaks the hydrophobic patch contributed by Y445, G446, G447, and Y449 in the RBD and V50, I51, Y53, G55, Y59, and Y105 in the H chain and displays steric clash with N57 in the H chain. The N440K mutation also displays a potential clash with Y102 in the H chain. These results suggest that REGN10987 fails to bind and neutralize BA.1, BA.1.1, and BA.3, all of which carry N440K and G446S mutations, whereas the mAb retains binding and neutralization against BA.2, owing to the lack of the G446S mutation.

G446S mutation impaired the efficacy of RBD-5 mAbs against Omicron

To confirm our hypothesis that G446S mutation impaired the efficiencies of RBD-5 mAbs, we further assessed the binding affinities of RBD-5 mAbs to BA.2 RBD with G446S by SPR assays. As expected, REGN10987, C110, and C119 showed decreased binding to BA.2 RBD with G446S mutation compared with those to BA.2 RBD (Figure 6). C135 and 47D11 displayed no binding to BA.2 RBD with G446S as to BA.2 RBD. S309 and 2H04 showed similar binding to BA.2 RBD with or without G446S, since this site is beyond their epitopes. However, the binding abilities of 2H04 to both RBDS are much lower than S309. Then, we evaluated the neutralizing potencies of these RBD-5 mAbs against BA.2 pseudovirus with G446S. We found that REGN10987, C110, and 2H04 completely lost neutralization, and C119, C135, and 47D11 showed no neutralization, against BA.2 pseudovirus with G446S (Figure 2). In contrast, S309 displayed similar neutralizing abilities against BA.2 pseudoviruses with or without G446S. These results were consistent with the SPR data. Additionally, the data indicated that the neutralizing activities of the mAbs in the other six groups were not affected by G446S mutation (Figure 2), which further supports our hypothesis.

The molecular basis of the immune evasion of mAbs targeting the inner face of RBD by Omicron

S304 and other antibodies in RBD-7 and RBD-6 recognize cryptic epitopes at the interface of RBD, require at least two RBDS in an up conformation for binding to the S trimer, and neutralize SARS-CoV-2 by partially clashing with ACE2 or

(C) Electrostatic surface view of Omicron BA.1 RBD.
(D) The overall comparison of two complex structures of BD-604/Prototype RBD and BD-604/BA.1 RBD by aligning the two RBDS. BD-604/Prototype RBD complex is shown as gray ribbon, and BD-604/BA.1 RBD is shown in the same color as in Figure 3A. Mutant residues in BA.1 RBD, that contributed to interaction with BD-604, are shown as spheres.
(E and F) The detailed interaction between H chain of BD-604 and the BA.1 RBD (E) or Prototype RBD (F). The residues involved in the interaction are labeled, and H-bonds are shown as dotted lines with a cutoff of 3.5 Å. (G and H) The detailed interaction between L chain of BD-604 and the BA.1 RBD (G) or Prototype RBD (H). The residues involved in the interaction are labeled, and H-bonds are shown as dotted lines with a cutoff of 3.5 Å.
(I-K) Binding face between RBD and representative mAbs, including CB6 (I), CC12.1 (J), and CC12.3 (K). All structures are shown in cartoon with the key residues in stick. H-bonds are shown as dotted lines with a cutoff of 3.5 Å. See also Tables S3 and S6.

1508 Immunity 55, 1501–1514, August 9, 2022
cross-linking spike proteins (Piccoli et al., 2020). In comparison with previously reported structures (Piccoli et al., 2020), we found that although no mutation in Omicron RBD was included in the binding face, the epitope of S304 was close to the S371L, S373P, and S375F mutations, which drives a conformational shift of the α2β2 loop (Figures 3F and 5D; Table S5). This shift destroyed the interaction of N370 with G55 and T57 in the H chain of S304 (Figure 5E; Table S5). Although S304 retained a relatively strong interaction with Omicron RBD as compared with that with Prototype RBD (Figures 5E and 5F; Table S5), it was ineffective in neutralizing Omicron because of the preferential conformation of Omicron in the one-RBD-up conformation. Similarly, the other mAbs in RBDb and RBDb-7 also showed weak neutralization ability against the Omicron variant, although their binding to Omicron RBD was equal to that to Prototype RBD and Delta RBD, except for H014, S2A4, and EY6A. H014 and S2A4 exhibited reduced binding and failed neutralization to Omicron. In contrast, EY6A showed slightly increased (approximately 3-fold) binding and decreased (approximately 5-fold) neutralization to Omicron (Figure 2). For S2A4, the S371L and S375F mutations break the H-bond interaction with R103 in the H chain and N32 in the L chain, respectively (Figure 5H). The S373P mutation and the shift of the α2β2 loop may increase the steric clash with the L chain. These two mutations also affect the binding of H014 to Omicron. These results lead to S2A4 and H014 showing relatively weak binding and disabled neutralization to Omicron sub-variants. Based on the reported structure of EY6A in complex with Prototype RBD (PDB: 6ZC2) or Omicron RBD (PDB: 7QNW) (Dejnirattisai et al., 2022), we found that S373P and S375F mutations enhanced H-bond interactions with K65 in the H chain (Figure 5I). In addition, S373P also increased the hydrophobic interaction with Y60, V64, G66, and F68 in the H chain (Figure 5I). These results could explain why EY6A enhanced binding to Omicron RBD (Figure 2). Taken together, EY6A still showed reduced neutralization against Omicron sub-variants due to the preferential conformation of Omicron S in one-RBD-up conformation.

**L452R mutation impaired the efficacy of RBDb-4 mAbs against Delta**

Compared with the four Omicron sub-variants, Delta carries a unique L452R mutation on RBD. Although the L452R is located in the RBM region, it does not directly participate in the interaction with ACE2 receptor (Han et al., 2022; Wang et al., 2020). However, as several studies reported, L452R mutation could reduce the sensitivity to mAbs and sera elicited by vaccines or infections based on the Prototype SARS-CoV-2, which increases the immune escape of Delta (Liu et al., 2021a; Planas et al., 2021b). In our study, we found Delta particularly escaped RBDb-4 mAbs due to the L452R mutation. As exemplified by BD-368-2, L452R mutation broke the hydrophobic interaction formed by G26, F27, A28, F29, Y32, and A33 on heavy chain of the mAb and Y449, Y451, Y453, and L455 on RBD and increased potential clash with T31 on heavy chain (Figure S5). Consequently, BD-368-2 showed 30-fold decreased binding to Delta RBD and failed neutralization against this variant (Figure 2).

**DISCUSSION**

Studies suggest that the Omicron BA.1 sub-variant is resistant to the majority of antibodies currently used against COVID-19. However, owing to the increasing prevalence of other sub-variants in many countries, the potential immune evasion of BA.1.1, BA.2, and BA.3 sub-variants needs to be clarified immediately. Herein, we selected 50 human neutralizing mAbs, recognizing seven classes of epitopes in the RBD, to compare immune evasions of BA.1, BA.1.1, BA.2, and BA.3 sub-variants. As expected, we found that BA.1.1, BA.2, and BA.3 showed immune escapes as remarkable as that of BA.1, indicating that these four sub-variants have similar evasion spectra. We noted, in particular, that BA.2 was more sensitive to RBDb-5 antibodies than BA.1, BA.1.1, and BA.3, owing to the lack of G446S mutation. As exemplified by RBDb-5 mAb REGN10987, G446S was crucial to impairing the binding of the antibody, destroying the strong hydrophobic patch formed by V445, G446, G447, and Y449 in the RBD and several hydrophobic residues in the antibody. As BA.2 has no G446S mutation, it retains some sensitivity to REGN10987. Our data further suggested that G446S impaired the efficacies of RBDb-5 mAbs by SPR and neutralization experiments. Additionally, the effect of G446S mutation was also confirmed by a recent study which found that this single mutation can impair the neutralizing ability of REGN10987 by more than 500-fold compared with the antibody against SARS-CoV-2 Prototype pseudovirus (Liu et al., 2022). Similarly, C110 and 2H04 also showed a little bit neutralizing ability against BA.2, but not BA.1 and BA.3, which include G446S.

Although some representative antibodies in RBDb-6 and RBDb-7 can bind BA.1, BA.1.1, BA.2, and BA.3 RBDs well, most of them showed weak or ineffective neutralization against these four sub-variants, which was consistent with the dominant state of
Omicron S in the one-RBD-up conformation as these two classes of antibodies recognize cryptic epitopes and require at least two RBDs in the up state. Free Omicron S proteins in two-RBD-up and three-RBD-down conformation have also been observed (Gobeil et al., 2022), and the complex structure of Omicron S in the two-RBD-up conformation bound to two ACE2s has been reported (Cui et al., 2022; Hong et al., 2022), indicating the limited conformational shift of Omicron S proteins and providing the structural basis to explain why RBD-6 and RBD-7 antibodies show certain neutralizing abilities against Omicron, although Omicron S proteins are preferentially in the one-RBD-up conformation. These results suggest that apart from the residue substitutions, the conformational shift of the S protein is also an important factor for immune evasion. However, many questions regarding the conformation of Omicron S still need to be answered. For example, further studies are required to clarify if the binding of ACE2 or an antibody to one RBD could induce a conformational change of the adjacent RBD.

The current strategies grouping COVID-19 antibodies are based on their epitope landscapes on SARS-CoV-2 Prototype RBD. However, with the emergence of Omicron, several reports as well as our study found that most antibodies exhibited completely or partially lost efficacies and few retained potencies against this variant, even if they belonged to the same epitope cluster. Therefore, new strategies for RBD groupings might be needed for Omicron. Here, we re-evaluated and classified these 50 mAbs into three groups according to them with or without Omicron binding (Figure S6A). Group 1 (G1) indicates the mAbs that can bind to the Omicron RBD and also confer neutralizing activities against Omicron sub-variants. This group contains 13 members, most of which belong to RBD-1, RBD-5, and RBD-6 in the Hastie’s system (Hastie et al., 2021). Group 2 (G2) indicates the mAbs that can bind to the Omicron RBD, but not neutralize Omicron VOC. This group includes 20 members, most of which belong to RBD-1, RBD-3, RBD-4, and RBD-7. Group 3 (G3) indicates the mAbs neither bind nor neutralize Omicron, containing 17 members, which mainly fall into RBD-1, RBD-2, and RBD-4 communities. These results imply the diversity of RBD-1 mAbs, due to their distribution of all three new identified groups. Notably, among these 50 mAbs, there are three superior mAbs (IC50 < 1 μg/mL) for Omicron, BD-604, S2E12, and S309, belong to RBD-1, RBD-2, and RBD-5, respectively (Figure S6B). However, these are three individual cases. Further studies are needed to determine the neutralizing
activities of mAbs against Omicron variants targeting these epitopes.

New variants and sub-lineages may continue to emerge in the future. With such high transmission levels, SARS-CoV-2 has abundant opportunity to reproduce and for errors or mutations to continue to arise. The way to address this issue is to try to slow transmission and reduce the pool of susceptible hosts in which the virus can freely replicate. Strategies such as social distancing and mask-wearing, as well as increasing global vaccination rates, will slow the emergence of new variants and lineages. Additionally, broad-spectrum vaccines and therapeutic antibodies are urgently needed to fight COVID-19. Antibodies such as BD-604 and S309, especially S309, which can recognize both up-RBD and down-RBD, should be the focus of future therapeutic development. Researchers should also enhance the stability of epitopes of these antibodies when designing vaccines. In addition, further studies to develop antibodies or peptides targeting the conserved S2 region of S proteins and small therapeutics targeting conserved polymerase or protease of SARS-CoV-2 are required to overcome the current Omicron sub-variants and future potential variants.

Limitations of the study
There are some limitations to the interpretation of this study. First, during the revision, new Omicron sub-variants (e.g., BA.4, BA.5, and BA.2.12.1) are emerging with different mutations and fast transmission, drawing public’s attention and concern. Thus, their immune evasion features should be investigated in the further study. Second, this study included 1 and 3 mAbs in RBD-3 and RBD-6 community, respectively, due to limited availability of RBD-3 and RBD-6 when we setup the experiments. However, more mAbs are being reported, and more members in the two communities should be evaluated in the further study for more accurate characterization of the immune evasion of Omicron sub-variants. Third, new neutralizing epitope of RBD has been identified, with the addition of the seven communities; thus, their neutralizing activities against Omicron sub-variants need further study.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Cells
- **METHOD DETAILS**
  - Gene construction
  - Protein expression and purification
  - SPR analysis
  - Pseudovirus neutralization assay
  - Cryo-EM data collection
  - Image process and 3D reconstruction
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

**SUPPLEMENTAL INFORMATION**
Supplemental information can be found online at https://doi.org/10.1016/j.immuni.2022.06.005

**ACKNOWLEDGMENTS**
We are grateful to Z. Fan (Institute of Microbiology, Chinese Academy of Sciences [CAS]) and Z. Yang (Tsinghua University) for their technical support of SPR analysis. We thank Novoprotein Scientific Inc. for their support on Omicron RBD expression. This work was supported by the CAS Project for Young Scientists in Basic Research (YSBR-010), the National Natural Science Foundation of China (81922044, 82041047, and 81973238), and the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29042203). L.W. is supported by the China Postdoctoral Science Foundation (2021M703446). Q.W. is supported by the Youth Innovation Promotion Association CAS (2018119).

**AUTHOR CONTRIBUTIONS**
Q.W. and G.F.G. initiated and coordinated the project. Q.W. designed the experiments. M.H. and Q.H. performed the SPR analysis. A.Z. and M.H. performed the pseudovirus neutralization assay. M.H. prepared the proteins of Omicron BA.1 RBD in complex with BD-604, S309, and S304. Y.X. collected the structural data and solved the cryo-EM structure. L.W., M.H., A.Z., Q.W., and G.F.G. analyzed the data. L.W., P.D., M.H., Q.W., and G.F.G. wrote the manuscript.

**DECLARATION OF INTERESTS**
The authors declare no competing interests.

Received: April 3, 2022
Revised: May 13, 2022
Accepted: June 5, 2022
Published: June 15, 2022

**REFERENCES**
Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). Phenix: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221. https://doi.org/10.1107/S090744490905292S.
Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020). Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell 182, 73–84.e16. https://doi.org/10.1016/j.cell.2020.05.025.
Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., et al. (2022). Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell 185, 860–871.e13. https://doi.org/10.1016/j.cell.2022.01.019.
Dejnirattisai, W., Huo, J., Zhou, D., Zahradnı́k, J., Supasa, P., Liu, C., Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., et al. (2022). Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell 185, 860–871.e13. https://doi.org/10.1016/j.cell.2022.01.019.
Du, P., Gao, G.F., and Wang, Q. (2022). The mysterious origins of the Omicron variant of SARS-CoV-2. Innovation (Camb) 3, 100206. https://doi.org/10.1016/j.im.x.2022.100206.
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132. https://doi.org/10.1107/S0907444904019158.
Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M.E., Tuekprakhon, A., Nutralai, R., et al. (2021). Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348–2361.e6. https://doi.org/10.1016/j.cell.2021.02.037.

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020). A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733. https://doi.org/10.1056/NEJMoa2001017.
## STAR* METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Bacterial Strains** |        |            |
| *Escherichia coli* (E. coli) strain DH5α | Vazyme | Cat# C502-02 |
| **Chemicals, antibody, and Recombinant Proteins** |        |            |
| Polyethylenimine (PEI) | Polysciences | Cat# 24885-2 |
| L-Cysteine · HCl · H₂O | Thermo scientific | Cat# 44889 |
| Immobilized Papain | Thermo scientific | Cat# 20341 |
| SARS-CoV-2 Prototype RBD protein with His-tag, spike residues 319-541 | This paper | GISAID:EPI_ISL_402119 |
| SARS-CoV-2 Delta RBD protein with His-tag, spike residues 319-541 | This paper | GISAID:EPI_ISL_2020954 |
| SARS-CoV-2 Omicron BA.1 RBD protein with His-tag, spike residues 319-541 | This paper | GISAID:EPI_ISL_6640916 |
| SARS-CoV-2 Omicron BA.1.1 RBD protein with His-tag, spike residues 319-541 | This paper | GISAID:EPI ISL_6704870 |
| SARS-CoV-2 Omicron BA.2 RBD protein with His-tag, spike residues 319-541 | This paper | GISAID:EPI ISL_9652748 |
| SARS-CoV-2 Omicron BA.2 RBD with G446S mutation protein with His-tag, spike residues 319-541 | This paper | GISAID:EPI ISL_9652748 |
| SARS-CoV-2 Omicron BA.3 RBD protein with His-tag, spike residues 319-541 | This paper | GISAID:EPI ISL_7605589 |
| **Critical Commercial Assays** |        |            |
| HisTrap HP 5 mL column | GE Healthcare | Cat# 17524802 |
| Protein A HP 5 mL column | GE Healthcare | Cat# 17040303 |
| HiLoad 16/600 Superdex 200 pg | GE Healthcare | Cat# 28989335 |
| Membrane concentrator | Millipore | UFC901096 |
| Series S Sensor Chip Protein A | GE Healthcare | Cat# 29127556 |
| **Deposited Data** |        |            |
| BD-604 Fab/S304 Fab/S309 Fab/Omicron BA.1 RBD (Cryo-EM) | This paper | Protein Data Bank: 7X1M |
| **Experimental Models: Cell Lines** |        |            |
| HEK293T cells | ATCC | ATCC CRL-3216 |
| HEK293F cells | Gibco | Cat# 11625-019 |
| Vero cells | ATCC | ATCC CCL-81 |
| I1-Hybridoma | ATCC | Cat# CRL2700 |
| **Recombinant DNA** |        |            |
| pCAGGS | MiaoLingPlasmid | Cat# P0165 |
| pCAGGS-mAbs | This paper | Sequence from PDB in Table S1 |
| pCAGGS-VSV-ΔG-GFP | This paper | N/A |
| pCAGGS-SARS-CoV-2 Prototype S | This paper | GISAID:EPI ISL_402119 |
| pCAGGS-SARS-CoV-2 Delta S | This paper | GISAID:EPI ISL_2020954 |
| pCAGGS-SARS-CoV-2 Omicron BA.1 S | This paper | GISAID:EPI ISL_6640916 |
| pCAGGS-SARS-CoV-2 Omicron BA.1.1 S | This paper | GISAID:EPI ISL_6704870 |
| pCAGGS-SARS-CoV-2 Omicron BA.2 S | This paper | GISAID:EPI ISL_9652748 |
| pCAGGS-SARS-CoV-2 Omicron BA.2 S with G446S mutation | This paper | GISAID:EPI ISL_9652748 |
| pCAGGS-SARS-CoV-2 Omicron BA.3 S | This paper | GISAID:EPI ISL_7605589 |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, George Fu Gao (gaof@im.ac.cn).

Materials availability
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Data and code availability
Cryo-EM density map and atomic coordinates have been deposited in the Electron Microscopy Data Bank and Protein Data Bank with the accession codes EMD-32944 and PDB: 7X1M, respectively.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cells
HEK293T cells (ATCC, CRL-3216) and Vero cells (ATCC, CCL81) were cultured at 37 °C in DMEM expression medium supplemented with 10% fetal bovine serum (FBS). HEK293F cells (Gibco, Cat# 11625-019) were cultured at 37 °C in SMM 293-TII expression medium (Sino Biological, Cat# M293TII) to express antibodies and RBDs. I1-Hybridoma was cultured at 37 °C in DMEM with 20% FBS.

METHOD DETAILS

Gene construction
The coding sequence of the variable region of each antibody was synthesized according to the amino acid sequences submitted to the Protein Data Bank. The heavy chains were fused with the constant region of human IgG1 and the light chains were fused with Igκ or Igλ, and both were cloned into the pCAGGS vector, respectively. The coding sequences of SARS-CoV-2 Prototype RBD (residues 319-541, GISAID:EPI_ISL_402119), Delta RBD (residues 319-541, GISAID:EPI_ISL_2020954), Omicron BA.1 RBD (residues 319-541, GISAID:EPI_ISL_6640916), Omicron BA.1.1 RBD (residues 319-541, GISAID:EPI_ISL_6704870), Omicron BA.2 RBD with or without G446S mutation (residues 319-541, GISAID:EPI_ISL_9652748), and Omicron BA.3 RBD (residues 319-541, GISAID:EPI_ISL_7605589) with a C-terminal 6 × His tag were cloned into the pCAGGS vector, respectively. The SARS-CoV-2 Prototype S, Delta S, Omicron BA.1 S, Omicron BA.1.1 S, Omicron BA.2 S with or without G446S mutation, and Omicron BA.3 S with an 18 amino acid truncation at the C-terminus were constructed into the pCAGGS vectors for pseudovirus preparation, respectively.

Protein expression and purification
The heavy and light chain plasmids of each antibody were transiently co-transfected into HEK293T cells at a ratio of 2:3 using polyethylenimine. After 6 h, the supernatant of HEK293T cells was replaced with DMEM without FBS. The supernatant was collected three days post-transfection for SPR analysis. The heavy and light chain plasmids of each antibody were also transiently co-transfected into HEK293F cells to express antibodies for the pseudovirus assay. Five days later, the supernatant of HEK293F cells was collected and antibodies were purified using Protein A 5 mL affinity columns (GE Healthcare). RBD proteins were expressed in HEK293F cells and purified using HisTrap HP 5 mL affinity columns (GE Healthcare). The soluble proteins were further purified by gel filtration using a Superdex™ 200 10/300 GL column (GE Healthcare). Fabs were generated by papain digestion and further purified using a Protein A column (S309 Fab and BD604 Fab) or Resource Q column (S304 Fab) and gel filtration using a Superdex™ 200...
10/300 GL column. RBDs and Fabs for crystallization were stored in buffer containing 20 mM Tris-HCl and 150 mM NaCl (pH 8.0). Antibodies and RBDs for SPR analysis were stored in PBS.

**SPR analysis**

The binding affinities and kinetics between RBDs and mAbs were analyzed using the BIAcore 8K (GE Healthcare) at 25 °C in the single-cycle mode. PBST buffer (10 mM Na2HPO4, 2 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH 7.4, and 0.005% (v/v) Tween 20) was used as the running buffer, and RBD proteins were changed into this buffer by gel filtration before use. First, culture supernatants containing the indicated antibodies were injected and captured on a Protein A chip (GE Healthcare). Serially diluted RBDs were then flowed over the surface of the chip to measure the binding response. Flow cell 1 was used as a negative control. 10 mM Glycine-HCl (pH 1.5) was used to regenerate the chips. The equilibrium dissociation constants ($K_D$) of each pair of interactions were calculated using a 1:1 (Langmuir) binding fit model with the BIAcore 8K evaluation software.

**Pseudovirus neutralization assay**

VSV-ΔG-GFP based SARS-CoV-2 Prototype, Delta variant, Omicron BA.1, Omicron BA.1.1, Omicron BA.2 with or without G446S mutation and Omicron BA.3 pseudoviruses were prepared as previously described (Zheng et al., 2022). Briefly, 30 µg of the plasmids encoding spike protein was transfected into HEK-293T cells; 24 h later, the VSV-ΔG-G-GFP pseudoviruses were added there. After 1 h of incubation, the HEK293T cell culture medium was removed and replaced with fresh complete DMEM medium containing 10 µg/mL of anti-VSV-G antibody (I1-Hybridoma ATCC® CRL2700). After another 30 h, supernatants containing VSV-ΔG-GFP based pseudoviruses were harvested, centrifuged, and filtered through a 0.45 µm sterilized membrane filter. The pseudoviruses were then aliquoted and stored at -80 °C until use.

For the neutralization assay, Vero cells were seeded in 96-well plates 12 h prior to infection. The antibodies were 4-fold serially diluted starting from 200 µg/mL. Then, 50 µL of the serially diluted antibodies were incubated with 50 µL of each pseudovirus at 1,000 transducing units at 37 °C for 1 h. The mixtures were then added to pre-plated Vero cells. After 15 h of incubation, transducing unit numbers were calculated using a CQ1 confocal image cytometer (Yokogawa).

**Cryo-EM data collection**

To prepare the cryo-EM sample, 4.0 µL of the BD-604/S309/S304/BA.1 RBD complex proteins at approximately 0.2 mg/mL was placed on the glow-discharged CryoMatrix R1.2/1.3 300-mesh grids (product no. M024-Au300-R12/13, Zhenjiang Lehua Technology Co., Ltd., China) and blotted for 2 s under a blot force of 0 at 4 °C and 100% humidity. The grids were immediately plunge-frozen in liquid ethane using a Vitrobot Mark IV (Thermo Fisher Scientific) and then transferred to a 300 kV Titan Krios transmission electron microscope equipped with a Gatan K3 detector and GIF Quantum energy filter. EPU software (Thermo Fisher Scientific) was used for automatic data collection. Movies were collected at 105,000 x magnification, with a calibrated pixel size of 0.85 Å. The defocus range was between -1.0 µm and -2.0 µm. Each movie was dose-fractionated into 32 frames with a total dose of 60 e-/Å².

**Image process and 3D reconstruction**

The detailed data-processing workflow is illustrated in Figure S4. A total of 8,354 super-resolution movies were collected and corrected for drift using MotionCor2 (Zheng et al., 2017), and the contrast transfer function (CTF) parameters were determined using patch CTF estimation implemented in cryoSPARC v.3.3.1 (Punjani et al., 2017). Blob particle picking, particle extraction, and 2D classification were performed on a subset of 583 micrographs. Good classes were selected and subjected to template picking, resulting in 6,930,593 particles. Junk particles were removed through multiple rounds of 2D classification, and a clean set of 1,444,508 particles was selected for the initial reconstruction and iterative heterogeneous refinement. A total of 553,923 particles were used for homogeneous refinement, yielding a 2.79 Å map. The structure model was built and refined using Phenix (Adams et al., 2010) and COOT (Emsley and Cowtan, 2004).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

**Binding analysis**

$K_D$ values of SPR experiments were obtained with BIAcore 8K Evaluation software (GE Healthcare), using a 1:1 binding model. The values indicate the mean ± SD of three independent experiments.

**Neutralization analysis**

IC$_{50}$ values of neutralization experiments were obtained using GraphPad Prism 8 software. The values were one representative results of two independent experiments.